Source comparison
Optimal Cycling Protocols: 8-Week-On, 4-Week-Off vs Continuous Administration
The standard tolerance to MK-677 cycling protocol in current research is 8 weeks on, 4 weeks off. This timing aligns with ghrelin receptor recovery kinetics demonstrated in rodent models published in Endocrinology (2021), where GHSR1a density returned to 85–90
This comparison does not assign a generated winner or score.
- The standard tolerance to MK-677 cycling protocol in current research is 8 weeks on, 4 weeks off. This timing aligns with ghrelin receptor recovery kinetics demonstrated in rodent models published in Endocrinology (2021), where GHSR1a density returned to 85–90% of baseline after 28 days of agonist withdrawal. Human pharmacokinetic data suggests similar recovery timelines. With MK-677's elimination half-life of 4–6 hours, complete drug clearance occurs within 24–36 hours, allowing receptor upregulation to begin almost immediately.
- Alternative protocols exist for different research objectives. The 12-week-on, 6-week-off protocol extends the administration phase for researchers prioritizing sustained anabolic effects, accepting slightly more receptor downregulation in exchange for longer active periods. This approach suits body composition studies where continuous anabolic stimulus matters more than peak GH pulse amplitude. Conversely, the 6-week-on, 3-week-off micro-cycle minimizes tolerance development entirely. IGF-1 levels rarely plateau within six weeks, making this the most conservative approach for long-term multi-year protocols.
- Continuous administration without cycling remains viable for specific research contexts: short-term studies (under 16 weeks), frailty research where appetite stimulation is the primary outcome, or protocols combining MK-677 with exogenous GH where receptor sensitivity is less critical. The key distinction: continuous protocols are not inherently inferior. They simply have a defined utility window. Expecting uninterrupted efficacy beyond 12 months contradicts the receptor biology.
- Standard Cycle
- 8 weeks
- 4 weeks
- General research, body composition studies
- Low. Receptors recover to 85–90% baseline
- Maintains 70–80% of initial IGF-1 elevation across multiple cycles
- Extended Cycle
- 12 weeks
- 6 weeks
- Anabolic research prioritizing continuous stimulus
- Moderate. Partial receptor downregulation by week 10–12
- Sustains 60–70% of peak IGF-1 response in subsequent cycles
- Micro-Cycle
- 3 weeks
- Long-term multi-year protocols, minimal tolerance priority
- Very Low. Negligible receptor adaptation within 6 weeks
- Preserves 80–90% of initial response indefinitely
- Continuous (No Cycling)
- 16+ weeks
- None
- Short-term studies, frailty research, appetite-focused protocols
- High. Significant receptor downregulation after 12 months
- IGF-1 levels stabilize at 40–50% of peak by month 8–12